# Ishara Investments LP 13F holdings Q2 2026: $136 million

Ishara Investments LP reported $136 million in 13F securities across 41 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Acadia Pharmaceuticals Inc at $10.4 million, 7.6% of the reported value. Since Q1 2026 it opened 16 new positions and exited 12.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $136,099,277
- Positions: 41
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 2111609
- Form 13F file number: 028-26490
- CRD number: 33186
- Business address: 8929 Exposition Blvd., Los Angeles, CA 90034
- SEC filing: [0002111609-26-000004](https://www.sec.gov/Archives/edgar/data/2111609/000211160926000004/0002111609-26-000004-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/ishara-investments-lp-331869)

## Top 25 holdings by value

The largest of 41 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Acadia Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/acadia-pharmaceuticals-inc-004225108) | COM | 410,000 | $10.4 million | +287,000 |
| [Xeris Biopharma Holdings Inc](https://specstream.ai/data/institutional-holders/xeris-biopharma-holdings-inc-98422e103) | COM | 1,230,000 | $9.7 million | +205,000 |
| [Biomarin Pharmaceutical Inc](https://specstream.ai/data/institutional-holders/biomarin-pharmaceutical-inc-09061g101) | COM | 143,500 | $8.2 million | +61,500 |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 22,550 | $7.5 million | No change |
| [Ultragenyx Pharmaceutical in](https://specstream.ai/data/institutional-holders/ultragenyx-pharmaceutical-in-90400d108) | COM | 205,000 | $6.8 million | +30,750 |
| [Agios Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/agios-pharmaceuticals-inc-00847x104) | COM | 164,000 | $6.1 million | New |
| [Insmed Inc](https://specstream.ai/data/institutional-holders/insmed-inc-457669307) | COM PAR $.01 | 51,250 | $5.5 million | New |
| [Crinetics Pharmaceuticals in](https://specstream.ai/data/institutional-holders/crinetics-pharmaceuticals-in-22663k107) | COM | 143,500 | $5.4 million | New |
| [Zentalis Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/zentalis-pharmaceuticals-inc-98943l107) | COM | 1,025,000 | $5 million | -205,000 |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 82,000 | $4.8 million | +24,600 |
| [Annexon Inc](https://specstream.ai/data/institutional-holders/annexon-inc-03589w102) | COM | 820,000 | $4.7 million | +645,750 |
| [Travere Therapeutics Inc](https://specstream.ai/data/institutional-holders/travere-therapeutics-inc-89422g107) | COM | 82,000 | $4.7 million | -28,700 |
| [Tonix Pharmaceuticals HLDG C](https://specstream.ai/data/institutional-holders/tonix-pharmaceuticals-hldg-c-890260839) | COM NEW | 338,250 | $4.3 million | New |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806x102) | COM | 57,400 | $4.3 million | New |
| [Axsome Therapeutics Inc.](https://specstream.ai/data/institutional-holders/axsome-therapeutics-inc-05464t104) | COM | 16,400 | $4 million | -24,600 |
| [Contineum Therapeutics Inc](https://specstream.ai/data/institutional-holders/contineum-therapeutics-inc-21217b100) | CL A | 205,000 | $3.4 million | +63,000 |
| [Lexicon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lexicon-pharmaceuticals-inc-528872302) | COM NEW | 1,271,000 | $3.1 million | +369,000 |
| [Kura Oncology Inc](https://specstream.ai/data/institutional-holders/kura-oncology-inc-50127t109) | COM | 276,750 | $3 million | New |
| [DBV Technologies S a](https://specstream.ai/data/institutional-holders/dbv-technologies-s-a-23306j309) | SPONSORED ADS | 184,500 | $3 million | +82,000 |
| [Genmab A/S](https://specstream.ai/data/institutional-holders/genmab-a-s-372303206) | SPONSORED ADS | 102,500 | $2.8 million | +20,500 |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 32,800 | $2.8 million | New |
| [Mineralys Therapeutics Inc](https://specstream.ai/data/institutional-holders/mineralys-therapeutics-inc-603170101) | COM | 102,500 | $2.8 million | +20,500 |
| [Silence Therapeutics PLC](https://specstream.ai/data/institutional-holders/silence-therapeutics-plc-82686q101) | ADS | 55,350 | $2.4 million | -85,150 |
| [Nuvation Bio Inc](https://specstream.ai/data/institutional-holders/nuvation-bio-inc-67080n101) | COM CL A | 369,000 | $2.1 million | New |
| [Wave Life Sciences LTD](https://specstream.ai/data/institutional-holders/wave-life-sciences-ltd-y95308105) | SHS | 328,000 | $1.9 million | New |

## New positions in Q2 2026

16 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Agios Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/agios-pharmaceuticals-inc-00847x104) | COM | 164,000 | $6.1 million |
| [Insmed Inc](https://specstream.ai/data/institutional-holders/insmed-inc-457669307) | COM PAR $.01 | 51,250 | $5.5 million |
| [Crinetics Pharmaceuticals in](https://specstream.ai/data/institutional-holders/crinetics-pharmaceuticals-in-22663k107) | COM | 143,500 | $5.4 million |
| [Tonix Pharmaceuticals HLDG C](https://specstream.ai/data/institutional-holders/tonix-pharmaceuticals-hldg-c-890260839) | COM NEW | 338,250 | $4.3 million |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806x102) | COM | 57,400 | $4.3 million |
| [Kura Oncology Inc](https://specstream.ai/data/institutional-holders/kura-oncology-inc-50127t109) | COM | 276,750 | $3 million |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 32,800 | $2.8 million |
| [Nuvation Bio Inc](https://specstream.ai/data/institutional-holders/nuvation-bio-inc-67080n101) | COM CL A | 369,000 | $2.1 million |
| [Wave Life Sciences LTD](https://specstream.ai/data/institutional-holders/wave-life-sciences-ltd-y95308105) | SHS | 328,000 | $1.9 million |
| [Nektar Therapeutics](https://specstream.ai/data/institutional-holders/nektar-therapeutics-640268306) | COM NEW | 26,650 | $1.9 million |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 32,800 | $1.7 million |
| [Vertex Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/vertex-pharmaceuticals-inc-92532f100) | COM | 2,460 | $1.2 million |
| [Ars Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/ars-pharmaceuticals-inc-82835w108) | COM | 143,490 | $1.1 million |
| [Monopar Therapeutics Inc](https://specstream.ai/data/institutional-holders/monopar-therapeutics-inc-61023l207) | COM NEW | 12,300 | $1.1 million |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 41,000 | $751,120 |
| [Mereo Biopharma Group PLC](https://specstream.ai/data/institutional-holders/mereo-biopharma-group-plc-589492107) | SPON ADS | 768,750 | $244,232 |

## Positions exited in Q2 2026

12 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Praxis Precision Medicines I | COM NEW (put) | 20,500 | $6.6 million |
| Kalvista Pharmaceuticals Inc | COM | 276,750 | $5.6 million |
| Amicus Therapeutic | COM | 369,000 | $5.3 million |
| [Verastem Inc](https://specstream.ai/data/institutional-holders/verastem-inc-92337c203) | COM NEW | 820,000 | $4.3 million |
| [Arrowhead Pharmaceuticals in](https://specstream.ai/data/institutional-holders/arrowhead-pharmaceuticals-in-04280a100) | COM | 55,350 | $3.5 million |
| [Moonlake Immunotherapeutics](https://specstream.ai/data/institutional-holders/moonlake-immunotherapeutics-61559x104) | CLASS A ORD | 174,250 | $3.2 million |
| [Ardelyx Inc](https://specstream.ai/data/institutional-holders/ardelyx-inc-039697107) | COM | 451,000 | $2.7 million |
| [Catalyst Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/catalyst-pharmaceuticals-inc-14888u101) | COM | 82,000 | $2 million |
| [Ligand Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/ligand-pharmaceuticals-inc-53220k504) | COM NEW | 8,200 | $1.6 million |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 49,200 | $1.5 million |
| [Ideaya Biosciences Inc](https://specstream.ai/data/institutional-holders/ideaya-biosciences-inc-45166a102) | COM | 24,600 | $819,672 |
| [PTC Therapeutics Inc](https://specstream.ai/data/institutional-holders/ptc-therapeutics-inc-69366j200) | COM | 10,250 | $698,333 |

## Also on SpecStream

- [Ishara Investments LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/2111609/000211160926000004/0002111609-26-000004-index.htm)
- [Ishara Investments LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/ishara-investments-lp-331869)
- [Largest 13F filers in California](https://specstream.ai/data/institutional-holdings/state/california)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Los Angeles, California

- [Electricians in Los Angeles, California](https://specstream.ai/data/businesses/electricians/los-angeles-california-united-states)
- [Employment agencies in Los Angeles, California](https://specstream.ai/data/businesses/employment-agencies/los-angeles-california-united-states)
- [Exporters in Los Angeles, California](https://specstream.ai/data/businesses/exporters/los-angeles-california-united-states)
- [Fast food restaurants in Los Angeles, California](https://specstream.ai/data/businesses/fast-food-restaurants/los-angeles-california-united-states)
- [Financial services firms in Los Angeles, California](https://specstream.ai/data/businesses/financial-services-firms/los-angeles-california-united-states)
- [Freight forwarders in Los Angeles, California](https://specstream.ai/data/businesses/freight-forwarders/los-angeles-california-united-states)
